Close

Jump to:

  • Navigation
  • Content
  • Footer
Whey Forward Health hero image

Whey Forward Health

Follow

Leading global multi-brand health & wellness company. Over 500,000 users and £7.5m revenue.

117%
 - 
Funded 9 May 2019
£700,002 target
£827,738 from 380 investors
More
Less

Business overview

Location Cardiff, United Kingdom
Social media
Website www.wheyforward.com
Sectors Home & Personal Non-Digital Mixed B2B/B2C
Company number 7832790
Incorporation date 2 Nov 2011
More
Less

Investment summary

Type Equity
Valuation (pre-money) £7.5M
Equity offered 9.81%
UK tax relief

EIS

  • Idea
  • Team
  • Updates
  • Investors 380
  • Discussion
  • Documents

Idea

Introduction

REGENATIVE is a patented daily health supplement that optimises cellular health, boosts performance and helps combat the effects of ageing. As far as we are aware, this is the first product of its kind.

We are uniquely positioned to leverage our established infrastructure to launch REGENATIVE with impact and significantly disrupt the global health supplement, anti-ageing and beauty markets.

PROMiXX is the World’s Best-Selling Vortex Mixer, trusted by elite athletes and more than 500,000 users across the globe. With the touch of a button, we revolutionised the way consumers mix their health supplements.

Following extensive R&D and feasibility testing, we are now poised to capitalise on our extensive brand equity and take the brand mass market!

We are pleased to announce our transition into the blender category with the release of two, highly innovative and IP-protected blender products.

Intended impact

In a fast-growing market, where more than 75% of Americans are now consuming health supplements, we saw the need for a premium solution for carrying, mixing and consuming powdered nutritional products.

We now aim to leverage our brand equity with a transition into the mass market blender category. We believe our unique combination of industry-leading innovation and striking design aesthetic will propel the brand and help us secure significant market share.

Antioxidants: we spend over $3 billion annually to give our levels a boost, yet most of us are unaware that the single most powerful antioxidant is produced naturally by the body and found inside every single one of our cells.

We're talking about 'Glutathione,' and levels inside our cells are considered one of the best indicators of our overall health and predictor of longevity.

REGENATIVE supports natural Glutathione production inside our cells - a pioneering natural health supplement with significant market potential!

Substantial accomplishments to date

• More than 500,000 users and brand advocates.
• Utilised seed funding of just £56,000 to generate over £7.5m of revenue.
• Over 7,500 pre-orders of our newest vortex mixer, MiiXR - Now due for launch in Q2/Q3 2019 - https://vimeo.com/201963706.
• Over 2 million social media fans/subscribers thanks to our industry-leading content.
• Recruited a large network of high profile brand advocates who freely endorse our products across their social channels.

• Winners of two enterprise awards, including a grant to develop the REGENATIVE formula.
• Secured significant intellectual property with a substantial (and growing) portfolio of international utility patents, trademarks and designs.
• Invitation-only members of the Amazon Launchpad Platform – showcasing products from “todays brightest startups”.
• Significant investment into R&D and new product development roadmap with significant product launches scheduled throughout the next 3 years.

• Secured listings in over 1,000 retail outlets including major retailers Argos and Holland & Barrett.
• Partnered with over 20 international distributors and landed products in over 50 countries.
• Achieved 'Best-Seller', 'Most Wished For' and 'Most Gifted' status on Amazon over multiple years.

• Acquired dozens of key domains, including .coms for all of our brands.
• Built a very talented and passionate team.
• Constructed state-of-the-art company headquarters in Cardiff, UK, with space for us to grow.

Monetisation strategy

Approximately 85% of revenue has been generated from direct-to-consumer sales via our global website (www.promixx.com) and 6 international Amazon marketplaces.

Following our domestic trade launch in October 2018, PROMiXX vortex mixers are now stocked in over 1,000 retail outlets throughout Europe including Argos and Holland & Barrett, as well as large specialty e-tailers Wiggle and Bodybuilding.com.

Note: the leading conventional shaker bottle brand is stocked in over 40,000 retail outlets in the US alone highlighting the size of the retail opportunity.

We have partnered with over 20 international distributors to whom we export directly from our manufacturing partners in China.

As a premium subscription model, REGENATIVE provides significant customer lifetime values and exciting potential for scale.

We plan for REGENATIVE to be available for purchase @ regenative.com, Amazon and specialty retailers.

Use of proceeds

Inventory - 40%
Increased inventory holding required to facilitate new market expansion and major retail credit terms.

New Product Development - 20%
Setup, tooling and mould costs for our new blender products.

Team - 10%
Key hires in Sales and Operations.

REGENATIVE Marketing - 10%
Digital advertising and influencer marketing campaigns.

Web & Systems - 5%
Implementation of new ecommerce platforms and custom ERP system.

IP - 5%
Strengthening our international patent and trademark protection.

Working Capital - 10%

NOTICE:
The company has three loans totalling £214,900 outstanding, broken down as follows:

1) Amazon loan: £56,600. 6 monthly repayments remaining.
2) ESME loan: £117,700. 47 monthly repayments remaining.
3) Private loan: £40,600. 10 monthly repayments remaining.

None of the proceeds raised will be used to fund these debts.

Please note that any discounts, rewards and/or offers listed by a company in its campaign are subject to the terms and conditions applied by that company and listed above. It is the company’s responsibility to honour such discounts, rewards and/or offers and Seedrs does not take any responsibility for them.

Learn more about who we are and what we've done in an edit of our 2018 Seedrs Video:

Open an account to get access to the team members of Whey Forward Health

Sign up

Already have an account? Log in

To comply with financial regulations, we can only show full campaign details to registered users.

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Share on:

Investing involves risks, including loss of capital, illiquidity, lack of dividends and dilution, and should be done only as part of a diversified portfolio. Please read the Risk Warnings before investing. Investments should only be made by investors who understand these risks. Tax treatment depends on individual circumstances and is subject to change in future.

This campaign for Whey Forward Health has been approved by Seedrs Limited (trading as Republic Europe) ("Republic Europe", "us" or "we"), as of 1 March 2019 as a financial promotion. Republic Europe is authorised and regulated by the Financial Conduct Authority with firm reference number 550317. In approving this campaign, Republic Europe has concluded that the information, taken as a whole, is "fair, clear and not misleading." This means that for factual statements we have reviewed evidence of their accuracy, and that for aspirational statements we believe they are phrased appropriately in light of their speculative nature. You should note that in the case of factual statements, the evidence we review is provided by the business, and we do not audit it, which means that we may not be able to identify forged or altered evidence. You should further note that in the case of aspirational statements, the nature of the type of businesses presented on the Republic Europe platform is such that they are likely to have high ambitions, and we may approve statements that convey those ambitions even where we do not believe, or we do not have a view on whether it is likely, that they will be fully realised. The pre-money valuation and investment sought in the campaign are those set by the business: they are not reviewed or established by us, and the valuation is not an independent view of what the business is worth. Given the nature and type of businesses presented on the Republic Europe platform, it is possible that the business has very little cash remaining prior to receiving this investment, and the investment sought may be necessary for the business's on-going existence.

Republic Europe does not make investment recommendations to you. No communications from Republic Europe, through this website or any other medium, should be construed as an investment recommendation. Further, nothing on this website shall be considered an offer to sell, or a solicitation of an offer to buy, any security to any person in any jurisdiction to whom or in which such offer, solicitation or sale is unlawful. Republic Europe does not provide legal, financial or tax advice of any kind. If you have any questions with respect to legal, financial or tax matters relevant to your interactions with Republic Europe, you should consult a professional adviser.

Tax Relief (SEIS)

This business is eligible for SEIS relief - providing qualifying investors with income tax relief of 50% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Tax Relief (EIS)

This business is eligible for EIS relief - providing qualifying investors with income tax relief of 30% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Valuation (pre-money)

Valuation rounded from £7,541,682

This is the fully-diluted pre-money valuation of the business (i.e. before the new investment comes in and including issued options and other equity interests). In contrast, the post-money valuation is based on inclusion of the new investment in the value.

It is calculated as the pre-money valuation plus the amount of new investment. e.g. If Company A is ascribed a pre-money valuation of £1,200,000 by prospective investors investing £300,000, its post-money valuation is £1,500,000.

The investee business is responsible for setting its own valuation, it has not been prescribed by Republic Europe.

Pitch type

Investing in a regular equity campaign is the simplest and most common way to invest in a startup. You decide which business you want to invest in, and if the campaign hits its funding target then you will become one of their shareholders. As the company becomes more valuable, so do your shares; allowing you the opportunity to share in the future success of the business.

Learn more about pitch type on Republic Europe

Equity Offered

The equity offered is the percentage of the company’s shares being issued in return for the amount of investment raised.

When the amount raised is less than 100%, the equity offered is based on the target raise. Once the company has raised over 100% it is based on the total raised.

In some scenarios, entrepreneurs may accept additional direct investment after closing their Republic Europe campaign. Provided this is within 6 months of the closing and on the same terms, we do not typically offer pre-emption rights on that extra investment (where you have the opportunity to invest again to maintain your percentage shareholding).

Learn more about investing and pre-emption rights.

Warning

You are following a link outside of europe.republic.com.

None of the information in constitutes part of the campaign and it has not been approved or reviewed by Republic Europe.

ContinueCancel